Capital Group Investment Management PTE. LTD. Has $3.35 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Capital Group Investment Management PTE. LTD. cut its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 15.7% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,956 shares of the biopharmaceutical company’s stock after selling 1,109 shares during the period. Capital Group Investment Management PTE. LTD.’s holdings in Regeneron Pharmaceuticals were worth $3,349,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Salomon & Ludwin LLC acquired a new position in shares of Regeneron Pharmaceuticals during the third quarter valued at about $27,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in Regeneron Pharmaceuticals during the second quarter worth about $31,000. Caitlin John LLC acquired a new stake in Regeneron Pharmaceuticals during the third quarter worth about $34,000. Traub Capital Management LLC bought a new position in Regeneron Pharmaceuticals during the second quarter valued at about $38,000. Finally, Berbice Capital Management LLC increased its stake in Regeneron Pharmaceuticals by 300.0% during the second quarter. Berbice Capital Management LLC now owns 80 shares of the biopharmaceutical company’s stock valued at $42,000 after acquiring an additional 60 shares during the period. Institutional investors own 83.31% of the company’s stock.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Huda Y. Zoghbi sold 1,638 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the completion of the transaction, the director directly owned 1,703 shares of the company’s stock, valued at approximately $1,330,604.99. This trade represents a 49.03% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $778.53, for a total transaction of $77,853.00. Following the completion of the sale, the director owned 17,803 shares in the company, valued at $13,860,169.59. This represents a 0.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 5,274 shares of company stock valued at $4,142,738. 7.02% of the stock is owned by insiders.

Wall Street Analyst Weigh In

REGN has been the subject of a number of research reports. Wall Street Zen downgraded Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Sunday. Royal Bank Of Canada boosted their price objective on Regeneron Pharmaceuticals from $745.00 to $765.00 and gave the company a “sector perform” rating in a research report on Monday, March 2nd. JPMorgan Chase & Co. upped their target price on Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the company an “overweight” rating in a research note on Monday, February 2nd. HSBC started coverage on Regeneron Pharmaceuticals in a research report on Monday, November 24th. They issued a “buy” rating and a $255.00 target price for the company. Finally, Oppenheimer reiterated an “outperform” rating and set a $865.00 price target (up from $750.00) on shares of Regeneron Pharmaceuticals in a research note on Monday, February 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $802.27.

Regeneron Pharmaceuticals Stock Up 2.9%

NASDAQ REGN opened at $781.60 on Tuesday. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $821.11. The company has a market capitalization of $82.63 billion, a price-to-earnings ratio of 18.81, a PEG ratio of 2.04 and a beta of 0.40. The stock’s 50 day moving average is $770.83 and its two-hundred day moving average is $690.73. The company has a current ratio of 4.13, a quick ratio of 3.39 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. The business had revenue of $3.88 billion during the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.Regeneron Pharmaceuticals’s quarterly revenue was up 2.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $12.07 EPS. Equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 5th. Shareholders of record on Friday, February 20th were paid a dividend of $0.94 per share. This is an increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. This represents a $3.76 annualized dividend and a yield of 0.5%. The ex-dividend date was Friday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 9.05%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.